Home / Healthcare / Pharmaceutical / U.S. Sickle Cell Disease Treatment Market

U.S. Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, FT-4202, and GBT021601)}], By End-user (Hospitals, Specialty Clinics, and Others), and Country Forecast, 2023-2030

Report Format: PDF | Latest Update: Dec, 2023 | Published Date: Nov, 2023 | Report ID: FBI108646 | Status : Published
  • 2022
  • 40
  • PRICE
  • $ 2850
    $ 3850
    $ 4850
    Buy Now

Healthcare Clients